Dr. Volas-Redd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
790 Church St NE
Ste 335
Marietta, GA 30060Phone+1 770-590-8311Fax+1 770-590-8313
Summary
- I am board-certified Medical Oncology. My medical education was completed at Penn State University Hershey medical center. My residency was at the Hospital of the University of Pennsylvania. I began my Hematology and oncology
fellowship at University Pennsylvania and then transferred to finish my clinical and research fellowship at Emory University in Atlanta Georgia. I have a strong focus in breast cancer as well as Neuro-Oncology. I am a principal investigator and sub PI under the Northside Hospital Cancer Institute. I have active privileges within the Wellstar system, Northside Hospital cherokee as well as Piedmont mountainside hospital
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1998 - 2000
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1997 - 1998- University of Pennsylvania Health SystemResidency, Internal Medicine, 1994 - 1997
Pennsylvania State University College of MedicineClass of 1994
Certifications & Licensure
GA State Medical License 1998 - 2025
PA State Medical License 1995 - 1998- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 13 citationsEfficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab
Clinical Breast Cancer. 2019-02-28 - 62 citationsRandomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Marta Penas-Prado, Kenneth R. Hess, Michael J. Fisch, Lore W. Lagrone, Morris D. Groves
Neuro-Oncology. 2015-02-01
Press Mentions
Get to Know Dr. Gena Volas Redd, a Physician Specializing in Advanced Cancer Treatment in GeorgiaSeptember 13th, 2019
With This Grant Renewal Comes New Initiatives and Grant Aims to Further Expand Cancer Research to a Broader Population and Include Underserved Populations in Cancer Research:July 16th, 2019
Latest Breast Cancer Clinical Trials and How to Join OneSeptember 18th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
